In breast cancer, Ta et al. found a correlation between SLC35A3 expression and immune cell infiltration, suggesting that SLC35A3, along with CD8+ T cells, could serve as a biomarker for assessing immunotherapy efficacy 13. This evidence concerns the gene SLC35A3 and breast carcinoma.